Trials / Completed
CompletedNCT02429193
Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA
An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label phase 2 multi-center study of abiraterone and enzalutamide in men with castration-resistant prostate cancer. Sixteen patients will be enrolled over 18 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abiraterone + prednisone | Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.) |
| DRUG | Enzalutamide | Enzalutamide (160 mg/day p.o.) |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2019-09-01
- Completion
- 2019-09-01
- First posted
- 2015-04-29
- Last updated
- 2020-01-13
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02429193. Inclusion in this directory is not an endorsement.